Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19.

Shafat, Tali; Grupel, Daniel; Porges, Tzvika; Levi, Itai; Yagel, Yael; Nesher, Lior

Shafat, Tali; Grupel, Daniel; Porges, Tzvika; Levi, Itai; Yagel, Yael; Nesher, Lior.

Affiliation

Shafat T; Infectious Diseases Institute, Soroka University Medical Center, and the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Grupel D; Clinical Research Center, Soroka University Medical Center, and the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Porges T; Infectious Diseases Institute, Soroka University Medical Center, and the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Levi I; Haematology Department, Soroka University Medical Center, and the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Yagel Y; Haematology Department, Soroka University Medical Center, and the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Nesher L; Infectious Diseases Institute, Soroka University Medical Center, and the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Br J Haematol ; 198(5): 826-829, 2022 09.

Article in En | MEDLINE | ID: mdl-35718461

Subject(s)
Key words

COVID-19; Haematological malignancies; SARS-CoV-2 infection; anti-CD20 monoclonal antibodies; obinutuzumab; rituximab

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Br J Haematol Year: 2022 Document type: Article Affiliation country: Israel Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google